Contract

Associate Director

Contracts Counsel

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Annual Short-Term Incentive + Annual Long-Term Incentive

New Haven, CT, USA

In Person

Category
Legal & Compliance (2)
,
Requirements
  • Juris Doctor (J.D.) from an American Bar Association-accredited law school; attorney in good standing with license to practice in the state where you reside
  • Minimum 3-5 years demonstrated experience independently drafting, reviewing, and negotiating contracts with substantial experience in pharmaceutical or biotechnology industry, including experience in a commercial stage company
  • Ability to analyze complex contracts and legal documents and provide concise, actionable feedback
  • Understanding of the unique risks and considerations for the life sciences industry to identify and mitigate risks through contracting, such as drug development and intellectual property considerations, privacy laws, and fraud and abuse laws
  • Strong attention to detail, organizational skills, and the ability to manage multiple tasks simultaneously
  • Excellent written and verbal communication skills with the ability to interact effectively with internal teams, external vendors, and legal counsel
  • Ability to work independently and as part of a collaborative, fast-paced team environment; positive, can-do attitude with growth-mindset and enterprise leader approach
  • Demonstrated business acumen; highly skilled at integrating legal advice with business acumen and sound judgment
  • Commitment to integrity and ethical conduct and ability to handle confidential and proprietary information with discretion and sound judgment
  • Ability to travel to HQ office 2-4x a month
Responsibilities
  • Own the triaging process of contract requests as they are received by the legal department
  • Draft, review and negotiate a high volume and wide range of agreements, including master services, statements of work, clinical research organization, clinical trial, supply, consulting, confidentiality, sponsored research, material transfer, and any related legal documents required to support the company goals and in accordance with Invivyd’s legal standards, independently, as well as in coordination with internal and external counsel (as applicable with complexity of agreement)
  • Coordinate and liaise with multiple internal stakeholders, outside counsel, and counterparties to ensure timely preparation, review, negotiation, execution, tracking, and management of contracts
  • Facilitate internal contract approval and execution in line with delegation of authority
  • Advise internal clients on contract interpretation, obligations, risk exposure, dispute resolution, and other legal matters in a pragmatic way that results in actionable business advice
  • Coordinate and collaborate with finance and the business to develop spend approval, reporting, and purchasing processes, and assist in managing obligations (e.g., milestones, deliverables, invoicing)
  • Assist in the training of junior contracting staff and/or outside resources, as applicable
  • Improve and maintain contract policies, procedures, and processes, including by reducing cycle times and increasing efficiency
  • Represent the legal department and/or contracts function on special projects and cross-functional initiatives; collaborate with other members of the legal department on internal initiatives
  • Own and train on the records retention policy
  • Support the culture of the legal department as a valued business partner by working collaboratively with key stakeholders (including senior management, internal clients, intellectual property, and finance), gaining a deep understanding of the business and its needs, and implementing a pragmatic approach to contracting consistent with those needs

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA Q4 2025 revenue hit $17.2M, up 31% sequentially.
  • VYD2311 Phase 3 trial fully enrolled, data due mid-2026 with FDA Fast Track.
  • Appointed Harvard epidemiologist Michael Mina as Chief Medical Officer.

What critics are saying

  • Kahn Swick & Foti investigates officers over Adagio's 2021 IPO.
  • Low COVID-19 attack rates fail VYD2311 trial by mid-2026.
  • FDA revokes PEMGARDA EUA due to NB.1.8.1 variant escape in 2026.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering.
  • Develops vaccine-alternative monoclonal antibodies for immunocompromised patients.
  • Targets COVID-19, RSV, measles with pediatric-first approach via REVOLUTION program.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Invivyd who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.